TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04941664

Intervention type: DRUG
Group type: OTHER
Intervention: 0.5% levobupivacaine
Description: This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELVA90) of cases of the aforementioned local anesthetic (LA), in order to produce the surgical anesthesia of the patients scheduled for shoulder surgeries. Based on the principal investigator's clinical experience, the initial volume of 8ml will be used. Depending on the success or failure of the superior trunk block, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 2ml. The upper dose limit of the study to minimize the potential for local anesthetic systemic toxicity will be 16ml and the lower dose limit will be 4ml, which will be of no clinical importance.
Study: NCT06396468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: sevoflurane (1-1.2 MAC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: 100-400 mcg/kg /min of propofol
Study: NCT06210269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Oral antibiotic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study: NCT05963100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-like CAR-T
Description: intravenous drip of TCR-like CAR-T with indicated doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-like CAR-T
Description: intravenous drip of TCR-like CAR-T with indicated doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-like CAR-T
Description: intravenous drip of TCR-like CAR-T with indicated doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-like CAR-T
Description: intravenous drip of TCR-like CAR-T with indicated doses
Study: NCT06369948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular Nerve Group (PENG) Block
Description: The PENG block will be performed with the patient in the supine position. A linear high-frequency ultrasound probe (GE LOGIQ/P7 ultrasound, korea/ L6-12RS probe) is initially placed in a transverse plane over the anterior inferior iliac spine (AIIS); the probe is turned slightly medial until the hyperechoic continuous shadow of the iliopubic eminence (IPE). The target will be the plane between the psoas tendon and pubic ramus. The skin puncture site will be anesthetized using lidocaine 2% after skin disinfection and draping. A 22-gauge, 100 mm echogenic needle (Spinocan, B. Braun Melsungen AG, Germany) will be inserted in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, 25 mL of the local anesthetic solution (bupivacaine 0.5%) was injected in 5 mL increments while observing for adequate fluid spread in this plane.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elective hip hemiarthroplasty without receiving a PENG block.
Description: elective hip hemiarthroplasty without receiving a PENG block.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% injection
Description: bupivacaine 0.5% injection
Study: NCT05783284

Intervention type: DEVICE
Intervention: Holocare Studio 2 (HS2)
Description: 3D HV
Study: NCT05474248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Diaphragmatic Breathing Training
Study: NCT06312371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
Study: NCT05364827

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CTCA
Description: CTCA performed in intervention arm patients prior to CTO PCI
Study: NCT04971551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Oral on an empty stomach
Study: NCT06114732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise behaviour change intervention + TENS
Description: MOSAIC: Participants in this group receive two 60-minute individual video telehealth consultations (on weeks one \& two) and two 20-minute follow-up telephone calls (weeks six \& 12) delivered at a convenient time over the internet. All sessions are delivered by a trained senior/band 6 physiotherapist. All participants randomized to this arm are provided with a pedometer and a patient manual which include information on intermittent claudication (IC), risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.~HF-TENS - TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin. Participants will be asked to use TENS during their everyday walking-based tasks, and any planned walking activity they undertake.
Study: NCT04655599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olorinab
Description: Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
Study: NCT05631626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301 - Dexmethylphenidate 25mg
Description: 25mg CTx-1301 (Dexmethylphenidate tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301 - Dexmethylphenidate 37.5mg
Description: 37.5mg CTx-1301 (Dexmethylphenidate tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301 - Dexmethylphenidate 50mg
Description: 50mg CTx-1301 (Dexmethylphenidate tablet)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05028842

Intervention type: OTHER
Intervention: No intervention
Description: None.This is an observational study

Intervention type: OTHER
Intervention: No intervention
Description: None.This is an observational study

Intervention type: OTHER
Intervention: No intervention
Description: None.This is an observational study
Study: NCT05137678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glibenclamide
Description: Glibenclamide was given orally or by nasal feeding
Study: NCT06196684

Intervention type: PROCEDURE
Intervention: Mitral allograft implantation
Description: Tricuspid valve replacement with mitral valve allograft
Study: NCT04844840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT05806203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity shockwave treatment to pelvic floor region plus typical physical therapy
Description: Treatment dose: 1,000 - 1,500 shocks, 2.5-3.0 Hz, 0.06-0.10 mJ/mm2 (Intensity of 6-8), 8 to 12 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham shockwave treatment plus typical physical therapy
Description: Inactive dose of shockwave treatment
Study: NCT06545201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RE001 T cell
Description: All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m\^2/days,-5,-4 days) and fludarabine (25-30mg/m\^2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.
Study: NCT05925595

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Iniettabile Ginocchio
Description: Knee injection of the investigational device( MD Iniettabile Ginocchio) versus active comparator (Jonexa).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device Iniettabile Ginocchio
Description: Knee injection of the investigational device( MD Iniettabile Ginocchio) versus active comparator (Jonexa).
Study: NCT05449977

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnose
Description: First, the participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, the 2-minute walk test, the International physical activity questionnaire, the SF-36 short form, and the World health organization quality of life questionnaire will be applied respectively.
Study: NCT06545149

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioNutri AR-1,
Description: intervention with fermented and nutritionally balanced food twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BioNutri AR-1,
Description: intervention with fermented and nutritionally balanced food twice a day
Study: NCT05527756

Intervention type: OTHER
Intervention: Scar Cosmesis Assessment and Rating (SCAR) scale
Description: The SCAR scale consists of two simple questions about symptoms (itch and pain) with yes/no response options that are responded to by the patient and six clinician-related items that are rated by observers through photos of the incisions. This scale includes both objective measurements and patient-reported symptoms

Intervention type: OTHER
Intervention: Scar Cosmesis Assessment and Rating (SCAR) scale
Description: The SCAR scale consists of two simple questions about symptoms (itch and pain) with yes/no response options that are responded to by the patient and six clinician-related items that are rated by observers through photos of the incisions. This scale includes both objective measurements and patient-reported symptoms

Intervention type: OTHER
Intervention: Numerical rating scale (NRS)
Description: The NRS scale, in which the patients score the cosmetic appearance of the scar from 0 to 10, is questioned.

Intervention type: OTHER
Intervention: Numerical rating scale (NRS)
Description: The NRS scale, in which the patients score the cosmetic appearance of the scar from 0 to 10, is questioned.
Study: NCT06497387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRG-1801
Description: PRG-1801 (BCMA-targeting CAR-T Cells)
Study: NCT06495658

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Participants will be asked to take a daily dose of prebiotic supplement for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: Participants will be asked to take a daily dose of prebiotic supplement for 8 weeks.
Study: NCT06303999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube
Description: The group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study: NCT06440564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG Laser irradiation
Description: The presented DALIR procedure differs in so far from a standard treatment that after exposure all accessible metal implant surfaces and the adjacent soft tissue is irradiated manually with the Er:YAG laser all over line-by-line with an intended overlap of approximately 10% at constant spot diameter.
Study: NCT05150964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audeo hearing aid
Description: receiver in the canal devices with custom earmolds
Study: NCT04941248

Intervention type: DEVICE
Intervention: total-body PET/CT(uEXPLORER , United Imaging Healthcare, China)
Description: This prospective study will enroll twenty-five patients, including nine healthy volunteers, sixteen patients with decreased cardiac function . All of them will have a whole-body PET/CT(uEXPLORER , United Imaging Healthcare, China) in our department, Renji Hospital.

Intervention type: DEVICE
Intervention: total-body PET/CT(uEXPLORER , United Imaging Healthcare, China)
Description: This prospective study will enroll twenty-five patients, including nine healthy volunteers, sixteen patients with decreased cardiac function . All of them will have a whole-body PET/CT(uEXPLORER , United Imaging Healthcare, China) in our department, Renji Hospital.
Study: NCT04985422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based Daily Ecological Momentary Intervention
Description: Interventions are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted 6 random times a day over the set intervention period (4 weeks) to complete brief EMA and EMI intervention actions) across contexts in daily lives for the reduction of depressive symptoms, as well as rumination distress, and improve functioning.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smartphone-based Weekly-delivered Information
Description: Information with simple actions for reducing depressive symptoms are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted weekly with a new set of information, together with a 5-min assessment. The information includes intervention actions provided in the EMI group.
Study: NCT04652453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatrics Bundle
Description: Enrolled participants in the intervention arm will receive all 3 bundle components: occupational therapy (in addition to physical therapy) upon enrollment in the ICU, a portable amplifying device upon enrollment in the ICU, and a de-prescribing intervention by the ICU pharmacist (in conjunction with the medical team) upon ICU-to-floor transfer.
Study: NCT06012903

Intervention type: OTHER
Intervention: Questionnaire Welbevinden
Description: A validated questionnaire recommended by the Flemish inspection of education to measure well-being in primary school children of the 4th, 5th and 6th grade.

Intervention type: OTHER
Intervention: Questionnaire Vancouver symptom score for dysfunctional elimination syndrome
Description: Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016.

Intervention type: OTHER
Intervention: Developmental Coordination Disorder Questionnaire
Description: Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning.

Intervention type: OTHER
Intervention: Questionnaire concerning LUTS, NDDs and treatment perceptions
Description: Unvalidated, complementary questions including the presence of LUTS, earlier diagnosis of bladder and/or boweldysfunction and neurodevelopmental disorders and perception concerning treatment characteristics.

Intervention type: OTHER
Intervention: Questionnaire about policies and practices regarding children's toilet use and drinking habits in the classroom
Description: These unvalidated questionnaire was based on the questionnaire developed by Ko et al. (2016) about the school's policies and practices regarding children's toilet use and drinking habits in the classroom, covering students in grades one through six. Epidemiological questions related to LUTS were added to complement the questionnaire.
Study: NCT05293353

Intervention type: OTHER
Intervention: NeoKare Breast Milk Fortifier
Description: Powdered product made from human breast milk used to increase nutritional content of mother's own breast milk
Study: NCT04826588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone sodium succinate 10 mg/kg intravenously
Description: Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human normal immunoglobulin (IVIg)
Description: Human normal immunoglobulin (IVIg) 2g/kg intravenously as a single dose in line with guidance for dosing and administration in Kawasaki disease
Study: NCT06181825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMET-BA (Common Elements Toolbox- Behavioral Activation)
Description: COMET-BA includes 4 online weekly modules which focus on elements of behavioral activation, including positive activity scheduling, avoidance reduction, values, and change plans.
Study: NCT05559996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injectable form of multifractional intercalated cross-linked hyaluronic acid (Armonia®, Regenyal, Italy)
Description: 2 mL of Armonia was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
Study: NCT05556109

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory serum biomarkers
Description: Measuring inflammatory serum biomarkers by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory serum biomarkers
Description: Measuring inflammatory serum biomarkers by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory serum biomarkers
Description: Measuring inflammatory serum biomarkers by ELISA
Study: NCT05467306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Navigator Enhanced PrEP Support
Description: Pharmacies randomized to the nurse-navigator model will receive tailored support counseling, in addition to receipt of standard PrEP services. Support counseling by nurse-navigators will provide educational messaging tailored to AGYW and actionable advice targeting PrEP persistence and adherence and/or FP topics, and will address participants' questions related to the content. Counseling will include adherence encouragement (IMB domain: motivation), PrEP efficacy and safety (IMB domain: information), self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications, IMB domain: behavioral skills) and strategies for remembering PrEP refill schedules. During enrollment, the nurse-navigator will explain that support counseling is voluntary and that the nurse will also be available at the pharmacy to address concerns or questions whenever they arise outside of scheduled visits.
Study: NCT04981899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 6 infusions of nivolumab at a fixed dose of 40 mg, 14 days apart, and infusion of nivolumab on day 0 of the NICE-40.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 5000 mg / m2, 24-hour infusion on day 2 of the NICE-40.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Optimized to get AUC = 5 (max. 800 mg) on day 2 of the NICE-40.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg / m2 intravenously on 1-3 days of the NICE-40.
Study: NCT05476575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hydrogen inhalation, 4% concentration, given via nasal cannula
Description: 4% hydrogen inhalation via nasal cannula perioperatively